Pancreatic Cancer Research

ResearcherTorrance Memorial Medical CenterActive in the last 2 years

Kimberly L. Johung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-6931-4599; OpenAlex author ID A5056682593. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 0, last author 5)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper, 1 trial · 2018: 2 papers · 2019: 1 paper, 1 trial · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 10

  1. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. Co-author DOI 10.1001/jamaoncol.2024.1575↗
  2. Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Co-author DOI 10.21037/jgo-21-202↗
  3. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Bor… Last author DOI 10.1097/mpa.0000000000001592↗
  4. Pancreatic Cancer Prediction Through an Artificial Neural Network. Co-author DOI 10.3389/frai.2019.00002↗
  5. Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. Last author DOI 10.21037/jgo.2018.03.07↗
  6. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Last author DOI 10.21037/jgo.2018.04.03↗
  7. A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease. Last author DOI 10.7759/cureus.1007↗
  8. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the Nation… Last author DOI 10.1002/cncr.29652↗
  9. Locally advanced unresectable pancreatic cancer. Co-author DOI 10.6092/1590-8577/2684↗
  10. Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Co-author DOI 10.1016/j.ijrobp.2011.08.008↗

Trials 2

  1. Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma Principal investigator NCT03991962↗
  2. Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma Principal investigator NCT03099265↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stacey Stein · 5 shared papers, 2018–2024 · strength 0.59
  2. Jill Lacy · 4 shared papers, 2018–2024 · strength 0.47
  3. Michael Cecchini · 3 shared papers, 2020–2024 · strength 0.39
  4. Bryan William Chang · 4 shared papers, 2012–2018 · strength 0.30
  5. Ronald R. Salem · 2 shared papers, 2020–2024 · strength 0.25
  6. Adriana Blakaj · 2 shared papers, 2018–2020 · strength 0.23
  7. Charles E. Rutter · 2 shared papers, 2015–2018 · strength 0.14
  8. Brandon R. Mancini · 2 shared papers, 2015–2018 · strength 0.14
  9. Timil H. Patel · 1 shared paper, 2021 · strength 0.14
  10. Charles H. Cha · 1 shared paper, 2024 · strength 0.14
  11. John W. Kunstman · 1 shared paper, 2024 · strength 0.14
  12. Guoping Cai · 1 shared paper, 2024 · strength 0.14
  13. Luisa F. Escobar‐Hoyos · 1 shared paper, 2024 · strength 0.14
  14. Mandar Deepak Muzumdar · 1 shared paper, 2024 · strength 0.14
  15. Adham Adel Jurdi · 1 shared paper, 2024 · strength 0.14
  16. Kenneth Reed Shroyer · 1 shared paper, 2024 · strength 0.14
  17. Muhammad Wasif Saif · 2 shared papers, 2012–2014 · strength 0.12
  18. Jay K. Pahade · 1 shared paper, 2020 · strength 0.11
  19. Wazir Muhammad · 1 shared paper, 2019 · strength 0.11
  20. Jun Deng · 1 shared paper, 2019 · strength 0.11
  21. James J. Farrell · 1 shared paper, 2019 · strength 0.11
  22. John M Stahl · 1 shared paper, 2017 · strength 0.09
  23. Howard S. Höchster · 1 shared paper, 2017 · strength 0.09
  24. Shane A. J. Lloyd · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.